13cisn[4(ethoxycarbonyl)phenyl]retinamide

Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the alpha subunit of the interleukin-4 receptor, thereby inhibiting IL-4 and IL-13 signaling. As a systemic immunomodulator, it has demonstrated efficacy in improving atopic dermatitis.

Rolinsatamab is a fully humanized selective monoclonal antibody that is a potent dual inhibitor of IL-4 and IL-13. Rolinsatamab chimeric antigen receptor sequence T cells. Rolinsatamab can be used to prevent and treat immune diseases.

Eblasakimab (ASLAN004) is a humanized monoclonal antibody targeting the IL-13 receptor alpha. By blocking IL-4 and IL-13 signaling through type 2 receptor inhibition, it can be used for studying atopic dermatitis.

Romilkimab (SAR156597) is a chimeric humanized immunoglobulin (Ig) antibody specifically designed to target interleukins 4 and 13 (IL-4 and IL-13) [1].

Rademikibart (CBP-201) is a human monoclonal antibody selective for IL-4Rα, exhibiting strong affinity with a KD of 20.7 pM for human IL-4Rα epitopes, without cross-reactivity to IL-4Rα from other species. It effectively inhibits IL-4 and IL-13-induced STAT6 signaling, TF-1 cell proliferation, and TARC production in PBMCs, showing promise for investigating moderate-to-severe Th2 inflammatory diseases [1].